Enterprise Value
-39.7M
Cash
170.8M
Avg Qtr Burn
-29.12M
Short % of Float
9.82%
Insider Ownership
1.96%
Institutional Own.
87.43%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AK006 (IV) Details Chronic urticaria | Phase 1 Initiation | |
Lirentelimab (AK002) (Siglec-8) Details Eosinophilic Esophagitis | Failed Discontinued | |
Lirentelimab (AK002) Details Atopic dermatitis | Failed Discontinued | |
Lirentelimab (AK002) (Siglec-8) Details Chronic urticaria | Failed Discontinued | |
Lirentelimab (AK002) (Siglec-8) Details Eosinophilic Duodentitis , Eosinophilic Gastritis | Failed Discontinued |